FIG 3.

Dependency of CD4 and CCR5 on de novo infection modulation by LRAs. (A) Intracellular p24 content was quantified in cells treated with LRAs for 24 h before incubation with Bal-HSA viruses (75 ng of p24) for 2 h. Results are represented as p24 concentration relative to untreated cells determined by ELISA (n = 4). (B to D) Cells were first treated for 8 h with LRAs and next infected for 16 h with Bal-HSA (B and C) or VSV-g-HSA (D) viruses. (B and C) Cells were cultured for another 24 h, after which total DNA was extracted to quantify total (B) and completed (C) HIV-1 RT products by qPCR (n = 3). Data are displayed as HIV-1 products copies relative to the untreated condition. EFZ (100 nM) treatment was used as a negative control of RT completion. (D) Cells were incubated for another 3 days in complete culture medium, and infection rate was assessed as the percentage of HSA-positive cells relative to untreated cells by flow cytometry (n = 6). One-way ANOVA with Dunnett’s multiple-comparison test was used (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.005; ****, P ≤ 0.001).